[go: up one dir, main page]

MX2022007961A - Nuevos anticuerpos anti-fgfr2b. - Google Patents

Nuevos anticuerpos anti-fgfr2b.

Info

Publication number
MX2022007961A
MX2022007961A MX2022007961A MX2022007961A MX2022007961A MX 2022007961 A MX2022007961 A MX 2022007961A MX 2022007961 A MX2022007961 A MX 2022007961A MX 2022007961 A MX2022007961 A MX 2022007961A MX 2022007961 A MX2022007961 A MX 2022007961A
Authority
MX
Mexico
Prior art keywords
novel anti
fgfr2b
antibodies
fgfr2b antibodies
same
Prior art date
Application number
MX2022007961A
Other languages
English (en)
Inventor
Zhenfan Yang
Yu Bai
Xiaolin Zhang
Mei Wang
Qiuli Guo
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of MX2022007961A publication Critical patent/MX2022007961A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • G01N33/5758—
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación proporciona anticuerpos anti-FGFR2b o fragmentos de unión a antígenos de estos, polinucleótidos aislados que codifican los mismos, composiciones farmacéuticas que los comprenden y los usos de estos.
MX2022007961A 2019-12-24 2020-12-23 Nuevos anticuerpos anti-fgfr2b. MX2022007961A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019127904 2019-12-24
PCT/CN2020/138659 WO2021129672A1 (en) 2019-12-24 2020-12-23 Novel anti-fgfr2b antibodies

Publications (1)

Publication Number Publication Date
MX2022007961A true MX2022007961A (es) 2022-07-12

Family

ID=76575671

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007961A MX2022007961A (es) 2019-12-24 2020-12-23 Nuevos anticuerpos anti-fgfr2b.

Country Status (11)

Country Link
US (1) US20230052680A1 (es)
EP (1) EP4081547A4 (es)
JP (1) JP7692419B2 (es)
KR (1) KR20220119144A (es)
CN (1) CN114846029A (es)
AR (1) AR120886A1 (es)
AU (1) AU2020412088A1 (es)
CA (1) CA3160812A1 (es)
MX (1) MX2022007961A (es)
TW (1) TWI861326B (es)
WO (1) WO2021129672A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220119143A (ko) * 2019-12-24 2022-08-26 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 신규한 항fgfr2b 항체
KR20250042203A (ko) * 2022-03-28 2025-03-26 항저우 종메이화동 파마슈티칼 컴퍼니 리미티드 신규한 항-fgfr2 항체
CN121039158A (zh) * 2023-03-31 2025-11-28 杭州中美华东制药有限公司 新型抗fgfr2抗体
CN118852431A (zh) * 2023-04-28 2024-10-29 武汉人福创新药物研发中心有限公司 抗FGFR2b单抗
CN118994393A (zh) * 2023-05-19 2024-11-22 广东东阳光药业股份有限公司 一种抗fgfr2抗体及其应用
TW202540177A (zh) * 2023-11-14 2025-10-16 大陸商蘇州創勝醫藥集團有限公司 抗－ＦＧＦＲ２ｂ免疫偶聯物及其於治療癌症的用途
WO2025130905A1 (zh) * 2023-12-18 2025-06-26 山东先声生物制药有限公司 抗FGFR2b抗体-药物缀合物及其应用
TW202542194A (zh) * 2024-01-05 2025-11-01 英屬開曼群島商百濟神州有限公司 抗ＦＧＦＲ２ｂ抗體、結合物及使用方法
CN120424212A (zh) * 2024-01-26 2025-08-05 上海安领科生物医药有限公司 抗FGFR2b抗体及抗体药物偶联物
CN118772279B (zh) * 2024-06-28 2025-03-25 北京普利米特生物科技有限公司 抗FGFR2b抗体或其抗原结合片段及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
LT3290052T (lt) * 2008-11-07 2020-02-25 Galaxy Biotech, Llc Monokloniniai antikūnai fibroblastų augimo faktoriaus receptoriui 2
CN105263962B (zh) * 2013-03-19 2019-12-31 北京盛诺基医药科技股份有限公司 抗体及用于治疗与雌激素受体相关疾病的方法
NZ715201A (en) 2013-08-01 2021-12-24 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
CN103757026B (zh) * 2013-12-20 2017-04-05 广州圣露生物技术有限公司 FGFR2b胞外段的基因序列、多肽及其应用
EP3380523A1 (en) * 2015-11-23 2018-10-03 Five Prime Therapeutics, Inc. Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
EP4650004A2 (en) * 2017-05-16 2025-11-19 Five Prime Therapeutics, Inc. Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment

Also Published As

Publication number Publication date
US20230052680A1 (en) 2023-02-16
EP4081547A4 (en) 2024-02-21
AR120886A1 (es) 2022-03-30
JP2023508174A (ja) 2023-03-01
TW202136311A (zh) 2021-10-01
AU2020412088A1 (en) 2022-06-23
JP7692419B2 (ja) 2025-06-13
TWI861326B (zh) 2024-11-11
KR20220119144A (ko) 2022-08-26
CN114846029A (zh) 2022-08-02
EP4081547A1 (en) 2022-11-02
CA3160812A1 (en) 2021-07-01
WO2021129672A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
CA3149406A1 (en) Novel anti-cldn18.2 antibodies
MX2022007961A (es) Nuevos anticuerpos anti-fgfr2b.
MX2022007959A (es) Nuevos anticuerpos anti-fgfr2b.
MX2024007966A (es) Anticuerpos anti-tslp novedosos.
MX2025009320A (es) Anticuerpos anti-cd19 novedosos
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
WO2020039321A3 (en) Anti-gdf15 antibodies, compositions and methods of use
PH12020551716A1 (en) Anti-ror antibody constructs
MX2023008423A (es) Anticuerpos anti-gremlin1 novedosos.
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
IL285651A (en) Anti-trem2 antibodies, preparations containing them and their uses
WO2017106684A3 (en) Antibodies specifically binding hla-dr and their uses
WO2018170351A8 (en) Anti-phf-tau antibodies and uses thereof
MX2019007021A (es) Anticuerpos il-11ra.
PH12020550078A1 (en) Novel anti-cd3epsilon antibodies
MX2022007960A (es) Nuevos anticuerpos anti-fgfr2b.
EP3957723A3 (en) Engineered ligase variants
WO2017214462A3 (en) Anti-cd98 antibodies and antibody drug conjugates
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
ZA202106602B (en) Claudin 6 antibodies and uses thereof
AU2019321490A8 (en) Ox40-binding polypeptides and uses thereof
WO2018069871A3 (en) Anti-kras binding proteins
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
EP4273165A3 (en) Interferon beta antibodies and uses thereof
WO2020260898A3 (en) Novel cancer antigens and methods